Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Biocon Biologics receives FDA approval for biosimilar YESINTEK
Biocon Biologics receives FDA approval for biosimilar YESINTEK (Ustekinumab-kfce), set to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The biosimilar will be commercialized in the US by February 2025 under a licensing agreement with Janssen.
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
FDA approves Yesintek (ustekinumab-kfce), a biosimilar to Stelara, for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Yesintek carries risks of infections, malignancies, hypersensitivity reactions, and other adverse effects.
Four Kildare STEM students receive major scholarships
Four Kildare students among 82 recipients of Johnson & Johnson’s WiSTEM2D Undergraduate Awards, recognizing outstanding female students in STEM2D disciplines. The awards, marking a 33% increase in recipients, highlight the program’s impact and Johnson & Johnson’s commitment to promoting female excellence in STEM.
Biocon Secures FDA Approval for Innovative Autoimmune Drug YESINTEK
Biocon Biologics received FDA approval for YESINTEK, a monoclonal antibody treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The drug targets inflammation-triggering proteins, offering new therapeutic options for autoimmune diseases. Biocon Biologics has a licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson for U.S. market commercialization, set to begin on February 22, 2025.
FDA Permits Using Johnson & Johnson Cancer Drug Without Chemo
FDA approves Janssen's Zytiga for mCRPC without prior chemo; European Medicines Agency also gives positive opinion. Johnson & Johnson shares rise.
USFDA gives nod to Biocon Biologics' biosimilar to treat Crohn's disease
Biocon Biologics Ltd announced FDA approval for YESINTEK, a biosimilar to Stelara, for treating Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis. The company had previously agreed with Janssen to commercialize YESINTEK in the U.S. post-FDA approval.
Kenosha County Public Health now offering harm reduction vending machines at 3 locations
Kenosha County Public Health offers harm reduction vending machines at three locations, providing Narcan, fentanyl test strips, and other items free of charge. Machines are available 24/7 at the WIC office and Sharing Center, and from 8 a.m. to 5 p.m. at the Job Center. The HOPE Council also offers a similar machine.
Biocon Biologics secures US FDA approval to commercialise YESINTEK
Biocon Biologics secures FDA approval for YESINTEK, a biosimilar for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, with plans to commercialise by February 22, 2025, following a licensing agreement with Janssen.
Biocon Biologics Receives US FDA Nod for Yesintek, A Biosimilar to J&J's Stelara
Biocon Biologics received FDA approval for Yesintek, a biosimilar for Stelara, treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. This marks a significant milestone for the company, aiming to provide affordable access to high-quality biosimilars globally. Biocon Biologics plans to commercialize Yesintek in the U.S. by February 2025, under a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson.
US FDA approves Biocon Biologics' YESINTEK for autoimmune diseases
FDA approves Biocon Biologics' YESINTEK, a monoclonal antibody for treating autoimmune conditions like Crohn’s disease and psoriasis. The approval offers a new treatment option and is part of a licensing agreement with Janssen Biotech Inc. for U.S. commercialization, aiming for a February 2025 launch.
© Copyright 2024. All Rights Reserved by MedPath